Doctor with patient. Image credit: Canva
Squamous cell carcinoma is a type of cancer that can cause tumors on the head and neck (HNSCC). Even with treatment, less than 50% of people with certain types of HNSCC survive for five years. Researchers are studying immunotherapy drugs that may help the immune system to fight the cancer.
A clinical trial led by Charalampos Floudas, M.D., D.M.Sc., M.S., Associate Research Physician in the Center for Immuno-Oncology, is researching a combination drug therapy, N-803 and pembrolizumab, with or without PD-L1 t-haNK cells, for adults with HNSCC.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06161545
NCI Protocol ID: IRB001564
Official Title: A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
